Mesoblast completes dosing in Phase 3 back pain trial
Mesoblast Limited says it has concluded patient dosing for its Phase 3 MSB-DR004 trial of rexlemestrocel-L in chronic low back pain linked to inflammatory degenerative disc disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.